Aptamer-target interaction descriptor
Aptamer-target interaction information
Interaction ID: 51
Aptamer sequence: GCCUUAGUAACGUGCUUUGAUGUCGAUUCGACAGGAGGC
Target unique ID: P00533
Aptamer ID Aptamer descriptor Target chemistry Target name Affinity Binding Conditions/Buffer PubMed ID
Apta_51 CL4 Protein EGFR_HUMAN 10 nM PBS with 0.01% BSA 21915281
Structure information of aptamer
Aptamer Sequence: GCCUUAGUAACGUGCUUUGAUGUCGAUUCGACAGGAGGC
The optimal secondary structure in dot-bracket notation: .............(((((..(((((...))))).)))))
The centroid secondary structure in dot-bracket notation: .............(((((..(((((...))))).)))))
The MFE structure
The Centroid structure
The mountain plot representation
Aptamer information
Type Detail Type Detail
Aptamer ID Apta_51 Description CL4
Aptamer chemistry RNA Length 39 nt
GC content 51.3% Molecular weight 12,053.74 Da
Molarity of 1 μg/μl solution 82.96 μM Number of G-quadruplexes No QGRS found
G-Score N/A Function Targeted therapy
Sequence GCCUUAGUAACGUGCUUUGAUGUCGAUUCGACAGGAGGC
Applications Inhibits EGFR-mediated signal pathways causing selective cell death
Target information
Type Detail Type Detail
Uniprot ID P00533 Protein name Epidermal growth factor receptor (EC 2.7.10.1) (Proto-oncogene c-ErbB-1) (Receptor tyrosine-protein kinase erbB-1)
Gene name(s) EGFR ERBB ERBB1 HER1 Organism Epidermal growth factor receptor (EC 2.7.10.1) (Proto-oncogene c-ErbB-1) (Receptor tyrosine-protein kinase erbB-1)
Status reviewed in uniprot database Length 1210
Mass 134,277 Activity regulation Endocytosis and inhibition of the activated EGFR by phosphatases like PTPRJ and PTPRK constitute immediate regulatory mechanisms
Involvement in disease Lung cancer (LNCR) Catalytic activity Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-[protein]
PDB ID(s)
1IVO;1M14;1M17;1MOX;1NQL;1XKK;1YY9;1Z9I;2EB2;2EB3;2GS2;2GS6;2GS7;2ITN;2ITO;2ITP;2ITQ;2ITT;2ITU;2ITV;2ITW;2ITX;2ITY;2ITZ;2J5E;2J5F;2J6M;2JIT;2JIU;2JIV;2KS1;2M0B;2M20;2N5S;2RF9;2RFD;2RFE;2RGP;3B2U;3B2V;3BEL;3BUO;3C09;3G5V;3G5Y;3GOP;3GT8;3IKA;3LZB;3NJP;3OB2;3OP0;3P0Y;3PFV;3POZ;3QWQ;3UG1;3UG2;3VJN;3VJO;3VRP;3VRR;3W2O;3W2P;3W2Q;3W2R;3W2S;3W32;3W33;4G5J;4G5P;4HJO;4I1Z;4I20;4I21;4I22;4I23;4I24;4JQ7;4JQ8;4JR3;4JRV;4KRL;4KRM;4KRO;4KRP;4LI5;4LL0;4LQM;4LRM;4R3P;4R3R;4R5S;4RIW;4RIX;4RIY;4RJ4;4RJ5;4RJ6;4RJ7;4RJ8;4TKS;4UIP;4UV7;4WD5;4WKQ;4WRG;4ZAU;4ZJV;4ZSE;5C8K;5C8M;5C8N;5CAL;5CAN;5CAO;5CAP;5CAQ;5CAS;5CAU;5CAV;5CNN;5CNO;5CZH;5CZI;5D41;5EDP;5EDQ;5EDR;5EM5;5EM6;5EM7;5EM8;5FED;5FEE;5FEQ;5GMP;5GNK;5GTY;5GTZ;5HCX;5HCY;5HCZ;5HG5;5HG7;5HG8;5HG9;5HIB;5HIC;5J9Y;5J9Z;5JEB;5LV6;5SX4;5SX5;5U8L;5UG8;5UG9;5UGA;5UGB;5UGC;5UWD;5WB7;5WB8;5X26;5X27;5X28;5X2A;5X2C;5X2F;5X2K;5XDK;5XDL;5XGM;5XGN;5XWD;5Y25;5Y9T;5YU9;5ZTO;5ZWJ;6ARU;6B3S;6D8E;6DUK;6JRJ;6JRK;6JRX;6JWL;6JX0;6JX4;6JXT;6JZ0;6LUB;6LUD;6P1D;6P1L;6P8Q;6S89;6S8A;6S9B;6S9C;6S9D;6TFU;6TFV;6TFW;6TFY;6TFZ;6TG0;6TG1;6V5N;6V5P;6V66;6V6K;6V6O;6VH4;6VHN;6VHP;6WA2;6WAK;6WXN;6XL4;6Z4B;6Z4D;7A2A;7A6I;7A6J;7A6K;7AEI;7AEM;7B85;7JXI;7JXK;7JXL;7JXM;7JXP;7JXQ;7JXW;7K1H;7K1I;7KXZ;7KY0;7LEN;7LFR;7LFS;7LG8;7LGS;7LTX;7OM4;7OXB;7SYD;7SYE;7SZ0;7SZ1;7SZ5;7SZ7;7TVD;
Function Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses.
Activity data
Interaction ID 51
Target type Protein
Target unique ID P00533
Activity 10 nM
Binding Conditions/Buffer

PBS with 0.01% BSA
Assay

Binding isotherm for CL4:EC-EGFR complexes. Kd value was derived by fitting bound CL4 versus the protein concentration to the equation Y = BmaxX/(Kd+X), where Bmax is the extrapolated maximal amount of RNA:protein complex bound. The specific binding was determined by subtracting the background values obtained with CL4sc from the values obtained with CL4
PubMed ID 21915281
Similar aptamers
Aptamer ID Aptamer chemistry Sequence Similarity
Apta_633 RNA GGCAUCGGAAAGUGGGUUGAUGUAAGUAACAGGCGAUGCC 60.00%
Apta_303 RNA CCUCCGGCUCAUACCUUUUCGAAGACAAGCUUCGACAGGAGG 59.52%
Apta_402 RNA GCCUGUAAGGUGGUCGGUGUGGCGAGUGUGUUAGGAGAGAUUGC 56.82%
Apta_269 RNA AACGCUCAACGUCAGAAGGCAACGUAUAGGCAAGCACACUUCGACAUGAGGC 55.77%
Apta_152 RNA UUACCACGCGCUCUUAACUGCUAGCGCCAUGGC 53.85%
Apta_606 RNA CGGUUGGAUGGGUGUUGGUGGUUUGUUGAGUCCAGGCGGC 52.50%
Apta_212 RNA AGGAAGGCUUUAGGUCUGAGAUCUCGGAAU 51.28%
Apta_378 RNA UGCUCUUAGAAUGGGACUAAGACACGGGAC 51.28%
Apta_634 RNA GGUCUUACGUCGUUCGCGACUAUUGGGAGACC 51.28%
Apta_1167 RNA GGCGCGAGGAAGGAGGUCUGAGGAGGUCACUGCGCC 51.28%
Apta_1292 RNA GGCACGUGUAUUACCCUAGUGGUCGACGUGCC 51.28%
Apta_243 RNA GCUUGAAGCUAGCAGUAAGACUAGCGCUACGGAUGGGUGUGCG 51.16%
Apta_426 RNA UGCCGCUAUAAUGCACGGAUUUAAUCGCCGUAGAAAAGCAUGUCAAAGCCG 50.98%
Apta_2 RNA GGGCUUCUCUGGUUAGACCAGAUUUGAGCCUGGGAGCUCUCUGGCUAACUAGGGAACCC 50.85%
Apta_242 RNA GCUUCCAGGAAGAGAAGUGUCAUGUGAUCAGUCCUGGUGGGUGG 50.00%
Apta_632 RNA GACGAGAAGGAGUGCUGGUUAUACUAGCGGUUAGGUCACUCGUC 50.00%
Apta_707 RNA GGCCUAAAACAUACCAGAUUUCGAUCUGGAGAGGUGAAGAAUUCGACCACCUAGGCCGGU 50.00%
Apta_1166 RNA GAUGUAACUGAAUGAAAUGGUGAAGGACGGGUCCAGUAGGCUGC 50.00%
Apta_424 RNA UGCUAGUAUAUCGCACGGAUUUAAUCGCCGUAGAAAAGCAUGUCAAAGCCG 49.02%
Apta_425 RNA UGCCGCCAUAUCACACGGAUUUAAUCGCCGUAGAAAAGCAUGUCAAAGCCG 49.02%

ABOUT

AptaDB is an online database we developed to integrate comprehensive information about aptamer.
The detail of this database is described here:

HELP CENTER

>Contact us
>LMMD Group
>School of Pharmacy

DEV TOOL
Page last updated at 2022-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 43962
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.